Rachel Coleman-Pierron
Endocrinology, Diabetes & Metabolism · Houma, LANPI 1740555101
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 26.3% of the total. Reporting peaked in 2019 at $677 and has fallen 63.3% since, to $248 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in LA, where the typical reported total is $3,044.
Across 108 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$536
- Lilly USA, LLC$383
- Amgen$207
- AstraZeneca$199
- Boehringer Ingelheim$133
- Abbott$113
- plus $468 from 13 others
What the payments were for
- Food & beverage$1,98197%
- Education$583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $536 |
| Lilly USA, LLC | 18 | $383 |
| Amgen | 7 | $207 |
| AstraZeneca | 11 | $199 |
| Boehringer Ingelheim | 3 | $133 |
| Abbott | 5 | $113 |
| Dexcom, Inc. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Zealand Pharma US, Inc. | 2 | $50 |
| Kyowa Kirin, Inc. | 2 | $48 |
| AbbVie | 3 | $45 |
| UCB, Inc. | 3 | $44 |
| Valeritas, Inc. | 2 | $31 |
| Merck | 2 | $31 |
| Sequel Med Tech, LLC | 1 | $27 |
| Shire North American Group Inc | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Kvk-tech, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,039 in reported general payments places this provider in the 40th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 492 | $815,182 |
| OzempicSemaglutide | 447 | $724,916 |
| JardianceEmpagliflozin | 379 | $437,251 |
| TrulicityDulaglutide | 171 | $284,689 |
| FarxigaDapagliflozin Propanediol | 151 | $191,698 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 85 | $93,940 |
| Tresiba Flextouch U-200Insulin Degludec | 73 | $87,409 |
| Tresiba Flextouch U-100Insulin Degludec | 95 | $80,171 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 29 | $47,272 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 166 | $34,908 |
| Novolog FlexpenInsulin Aspart | 86 | $32,880 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $29,559 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $26,981 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 15 | $26,976 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $26,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog, Insulin Lispro | $383 | $1,129,242771 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $536 | $750,661495 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $133 | $547,618481 claims |
| AstraZenecaFarxiga | $199 | $191,698151 claims |
| MerckJanuvia, Janumet Xr | $31 | $36,36437 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $58 | $12,82215 claims |
| AbbVieSynthroid | $45 | $5,62072 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Houma
- David SisamHouma$13K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.